Confirming Multiplex RT-qPCR Use in COVID-19 with Next-Generation Sequencing: Strategies for Epidemiological Advantage
Global Health · 30.07.2022 · 2022 · 1-10
DOI: 10.1155/2022/2270965 ↗Kurz gefasst
Fachartikel in der Zeitschrift Global Health, erschienen am 30.07.2022. Verfasst von Rob E Carpenter und 4 weiteren Autor:innen. Beteiligte Einrichtung: Advanta Genetics, 10935 CR 159, Tyler, TX 75703, USA. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Rapid identification and tracking of emerging SARS-CoV-2 variants are critical for understanding the transmission dynamics and developing strategies for interrupting the transmission chain. Next-Generation Sequencing (NGS) is an exceptional tool for whole-genome analysis and deciphering new mutations. The technique has been instrumental in identifying the variants of concern (VOC) and tracking this pandemic. However, NGS is complex and expensive for large-scale adoption, and epidemiological monitoring with NGS alone could be unattainable in limited-resource settings. In this study, we explored the application of RT-qPCR-based detection of the variant identified by NGS. We analyzed a total of 78 deidentified samples that screened positive for SARS-CoV-2 from two timeframes, August 2020 and July 2021. All 78 samples were classified into WHO lineages by whole-genome sequencing and then compared with two commercially available RT-qPCR assays for spike protein mutation(s). The data showed good concordance between RT-qPCR and NGS analysis for specific SARS-CoV-2 lineages and characteristic mutations. RT-qPCR assays are quick and cost-effective and thus can be implemented in synergy with NGS for screening NGS-identified mutations of SARS-CoV-2 for clinical and epidemiological interest. Strategic use of NGS and RT-qPCR can offer several COVID-19 epidemiological advantages.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Advanta Genetics, 10935 CR 159, Tyler, TX 75703, USA.
- University of Texas at Tyler, 3900 University Boulevard, Tyler, TX 75799, USA.
- ICMR-National Institute of Research in Tribal Health, Jabalpur, MP 482003, India.
- RetroBioTech LLC, Coppell, TX 75019, USA.
- University of Miami Miller School of Medicine, 1600 NW 10th Ave, Miami, FL 33136, USA.
ORCID-Profile: Rob E Carpenter, Vaibhav Tamrakar, Harendra Chahar, Tyler Vine, Rahul Sharma
Zitieren
APA
Carpenter, R. E., Tamrakar, V., Chahar, H., Vine, T., & Sharma, R. (2022). Confirming Multiplex RT-qPCR Use in COVID-19 with Next-Generation Sequencing: Strategies for Epidemiological Advantage. Global Health, 2022, 1-10. https://doi.org/10.1155/2022/2270965
Vancouver
Carpenter RE, Tamrakar V, Chahar H, Vine T, Sharma R. Confirming Multiplex RT-qPCR Use in COVID-19 with Next-Generation Sequencing: Strategies for Epidemiological Advantage. Global Health. 2022;2022:1-10. doi:10.1155/2022/2270965
BibTeX
@article{Carpenter2022,
author = {Carpenter, Rob E and Tamrakar, Vaibhav and Chahar, Harendra and Vine, Tyler and Sharma, Rahul},
title = {Confirming Multiplex RT-qPCR Use in COVID-19 with Next-Generation Sequencing: Strategies for Epidemiological Advantage},
journal = {Global Health},
year = {2022},
volume = {2022},
pages = {1--10},
doi = {10.1155/2022/2270965}
}
EUVIMED